Cargando…
A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study
OBJECTIVE: This paper explores the use of pharmacoeconomic methods of valuation to health impacts resulting from exposure to poor air quality. In using such methods, interventions that reduce exposure to poor air quality can be directly compared, in terms of value for money (or cost-effectiveness),...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916570/ https://www.ncbi.nlm.nih.gov/pubmed/27329439 http://dx.doi.org/10.1136/bmjopen-2015-010686 |
_version_ | 1782438850969206784 |
---|---|
author | Lomas, James Schmitt, Laetitia Jones, Sally McGeorge, Maureen Bates, Elizabeth Holland, Mike Cooper, Duncan Crowther, Richard Ashmore, Mike Rojas-Rueda, David Weatherly, Helen Richardson, Gerry Bojke, Laura |
author_facet | Lomas, James Schmitt, Laetitia Jones, Sally McGeorge, Maureen Bates, Elizabeth Holland, Mike Cooper, Duncan Crowther, Richard Ashmore, Mike Rojas-Rueda, David Weatherly, Helen Richardson, Gerry Bojke, Laura |
author_sort | Lomas, James |
collection | PubMed |
description | OBJECTIVE: This paper explores the use of pharmacoeconomic methods of valuation to health impacts resulting from exposure to poor air quality. In using such methods, interventions that reduce exposure to poor air quality can be directly compared, in terms of value for money (or cost-effectiveness), with competing demands for finite resources, including other public health interventions. DESIGN: Using results estimated as part of a health impact assessment regarding a West Yorkshire Low Emission Zone strategy, this paper quantifies cost-saving and health-improving implications of transport policy through its impact on air quality. DATA SOURCE: Estimates of health-related quality of life and the National Health Service (NHS)/Personal Social Services (PSS) costs for identified health events were based on data from Leeds and Bradford using peer-reviewed publications or Office for National Statistics releases. POPULATION: Inhabitants of the area within the outer ring roads of Leeds and Bradford. MAIN OUTCOMES MEASURES: NHS and PSS costs and quality-adjusted life years (QALYs). RESULTS: Averting an all-cause mortality death generates 8.4 QALYs. Each coronary event avoided saves £28 000 in NHS/PSS costs and generates 1.1 QALYs. For every fewer case of childhood asthma, there will be NHS/PSS cost saving of £3000 and a health benefit of 0.9 QALYs. A single term, low birthweight birth avoided saves £2000 in NHS/PSS costs. Preventing a preterm birth saves £24 000 in NHS/PSS costs and generates 1.3 QALYs. A scenario modelled in the West Yorkshire Low Emission Zone Feasibility Study, where pre-EURO 4 buses and HGVs are upgraded to EURO 6 by 2016 generates an annual benefit of £2.08 million and a one-off benefit of £3.3 million compared with a net present value cost of implementation of £6.3 million. CONCLUSIONS: Interventions to improve air quality and health should be evaluated and where improvement of population health is the primary objective, cost-effectiveness analysis using a NHS/PSS costs and QALYs framework is an appropriate methodology. |
format | Online Article Text |
id | pubmed-4916570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49165702016-06-24 A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study Lomas, James Schmitt, Laetitia Jones, Sally McGeorge, Maureen Bates, Elizabeth Holland, Mike Cooper, Duncan Crowther, Richard Ashmore, Mike Rojas-Rueda, David Weatherly, Helen Richardson, Gerry Bojke, Laura BMJ Open Public Health OBJECTIVE: This paper explores the use of pharmacoeconomic methods of valuation to health impacts resulting from exposure to poor air quality. In using such methods, interventions that reduce exposure to poor air quality can be directly compared, in terms of value for money (or cost-effectiveness), with competing demands for finite resources, including other public health interventions. DESIGN: Using results estimated as part of a health impact assessment regarding a West Yorkshire Low Emission Zone strategy, this paper quantifies cost-saving and health-improving implications of transport policy through its impact on air quality. DATA SOURCE: Estimates of health-related quality of life and the National Health Service (NHS)/Personal Social Services (PSS) costs for identified health events were based on data from Leeds and Bradford using peer-reviewed publications or Office for National Statistics releases. POPULATION: Inhabitants of the area within the outer ring roads of Leeds and Bradford. MAIN OUTCOMES MEASURES: NHS and PSS costs and quality-adjusted life years (QALYs). RESULTS: Averting an all-cause mortality death generates 8.4 QALYs. Each coronary event avoided saves £28 000 in NHS/PSS costs and generates 1.1 QALYs. For every fewer case of childhood asthma, there will be NHS/PSS cost saving of £3000 and a health benefit of 0.9 QALYs. A single term, low birthweight birth avoided saves £2000 in NHS/PSS costs. Preventing a preterm birth saves £24 000 in NHS/PSS costs and generates 1.3 QALYs. A scenario modelled in the West Yorkshire Low Emission Zone Feasibility Study, where pre-EURO 4 buses and HGVs are upgraded to EURO 6 by 2016 generates an annual benefit of £2.08 million and a one-off benefit of £3.3 million compared with a net present value cost of implementation of £6.3 million. CONCLUSIONS: Interventions to improve air quality and health should be evaluated and where improvement of population health is the primary objective, cost-effectiveness analysis using a NHS/PSS costs and QALYs framework is an appropriate methodology. BMJ Publishing Group 2016-06-21 /pmc/articles/PMC4916570/ /pubmed/27329439 http://dx.doi.org/10.1136/bmjopen-2015-010686 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Public Health Lomas, James Schmitt, Laetitia Jones, Sally McGeorge, Maureen Bates, Elizabeth Holland, Mike Cooper, Duncan Crowther, Richard Ashmore, Mike Rojas-Rueda, David Weatherly, Helen Richardson, Gerry Bojke, Laura A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study |
title | A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study |
title_full | A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study |
title_fullStr | A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study |
title_full_unstemmed | A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study |
title_short | A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study |
title_sort | pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916570/ https://www.ncbi.nlm.nih.gov/pubmed/27329439 http://dx.doi.org/10.1136/bmjopen-2015-010686 |
work_keys_str_mv | AT lomasjames apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT schmittlaetitia apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT jonessally apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT mcgeorgemaureen apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT bateselizabeth apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT hollandmike apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT cooperduncan apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT crowtherrichard apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT ashmoremike apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT rojasruedadavid apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT weatherlyhelen apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT richardsongerry apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT bojkelaura apharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT lomasjames pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT schmittlaetitia pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT jonessally pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT mcgeorgemaureen pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT bateselizabeth pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT hollandmike pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT cooperduncan pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT crowtherrichard pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT ashmoremike pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT rojasruedadavid pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT weatherlyhelen pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT richardsongerry pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy AT bojkelaura pharmacoeconomicapproachtoassessingthecostsandbenefitsofairqualityinterventionsthatimprovehealthacasestudy |